Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

Fabrizio De Benedetti, HI Brunner, Nicolino Ruperto, Rayfel Schneider, Patricia Woo, Rubén Burgos‐Vargas, Pavla Doležalová, Rik Joos, N Wulffraat, Zbyszek Zuber,

Pediatric Rheumatology · 2011 · 20 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Purpose Treatment options for sJIA are limited. Excessive IL-6 production has been implicated in several manifestations of this disease. In a previous Japanese study, TCZ, an IL-6 receptor inhibitor, improved arthritis and systemic features of patients with refractory sJIA. We present efficacy and safety of TCZ in patients with active sJIA who were treated for ≥52 wks in the global, 3-part, 5-yr, phase 3, multicenter TENDER study. Methods